Published in Neuroimage Clin on June 13, 2013
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med (2015) 1.09
Seemingly unrelated regression empowers detection of network failure in dementia. Neurobiol Aging (2014) 0.86
Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. Acta Neuropathol Commun (2014) 0.86
Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings. Trends Cogn Sci (2013) 0.83
Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease. J Alzheimers Dis (2016) 0.81
Neuroimaging genetic risk for Alzheimer's disease in preclinical individuals: From candidate genes to polygenic approaches. Biol Psychiatry Cogn Neurosci Neuroimaging (2016) 0.80
The Role of PICALM in Alzheimer's Disease. Mol Neurobiol (2014) 0.79
Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimers Dement (2015) 0.79
An Alzheimer's Disease Genetic Risk Score Predicts Longitudinal Thinning of Hippocampal Complex Subregions in Healthy Older Adults. eNeuro (2016) 0.78
Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials. Alzheimer Dis Assoc Disord (2016) 0.75
Meta-analysis of association between the genetic polymorphisms on chromosome 11q and Alzheimer's disease susceptibility. Int J Clin Exp Med (2015) 0.75
The effect of the top 20 Alzheimer disease risk genes on gray-matter density and FDG PET brain metabolism. Alzheimers Dement (Amst) (2016) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology (1993) 47.72
A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging (1998) 23.54
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet (2007) 12.13
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science (2012) 10.42
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage (2005) 8.50
Monetary costs of dementia in the United States. N Engl J Med (2013) 6.77
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Mini-Mental State Examination (MMSE). Psychopharmacol Bull (1988) 4.11
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage (2006) 3.85
Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am J Epidemiol (2007) 3.48
Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med (2013) 3.25
Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol (2009) 2.95
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Inverse consistent mapping in 3D deformable image registration: its construction and statistical properties. Inf Process Med Imaging (2005) 2.87
Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One (2009) 2.85
Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement (2010) 2.79
Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol (2010) 2.76
A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J (2009) 2.66
Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet (2010) 2.51
Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage (2010) 2.32
Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain (2008) 2.28
Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage (2009) 2.28
Robust brain extraction across datasets and comparison with publicly available methods. IEEE Trans Med Imaging (2011) 2.22
Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging (2010) 2.13
The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement (2010) 2.09
Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging (2010) 2.05
Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol (2010) 2.02
Comprehensive search for Alzheimer disease susceptibility loci in the APOE region. Arch Neurol (2012) 1.97
Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease. Neuroimage (2010) 1.94
Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers. Neuroimage (2008) 1.83
Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials. Neuroimage (2012) 1.76
Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci (2011) 1.74
Voxelwise gene-wide association study (vGeneWAS): multivariate gene-based association testing in 731 elderly subjects. Neuroimage (2011) 1.48
Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry. Neuroimage (2011) 1.44
The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet (2010) 1.41
Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Arch Neurol (2011) 1.34
Television watching, leisure time physical activity, and the genetic predisposition in relation to body mass index in women and men. Circulation (2012) 1.33
Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord (2010) 1.33
Enhanced signal detection in neuroimaging by means of regional control of the global false discovery rate. Neuroimage (2007) 1.31
Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? J Neurol Neurosurg Psychiatry (2005) 1.21
Effects of ApoE-epsilon4 allele load and age on the rates of grey matter and hippocampal volumes loss in a longitudinal cohort of 1186 healthy elderly persons. Neuroimage (2010) 1.19
Neuroimaging measures as endophenotypes in Alzheimer's disease. Int J Alzheimers Dis (2011) 1.04
Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Ann Hum Genet (2013) 1.02
Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiol Aging (2010) 1.01
Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiol Aging (2011) 1.00
Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov (2002) 0.96
The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety. Neuropsychopharmacology (2008) 0.95
CR1 genotype is associated with entorhinal cortex volume in young healthy adults. Neurobiol Aging (2011) 0.87
Implication of common and disease specific variants in CLU, CR1, and PICALM. Neurobiol Aging (2012) 0.86
Alzheimer disease: BIN1 variant increases risk of Alzheimer disease through tau. Nat Rev Neurol (2013) 0.82
Genotype-based risk and pharmacogenetic sampling in clinical trials. J Biopharm Stat (2010) 0.81
Exhaustive search of the SNP-sNP interactome identifies epistatic effects on brain volume in two cohorts. Med Image Comput Comput Assist Interv (2013) 0.80
Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients. Dement Geriatr Cogn Dis Extra (2011) 0.75
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci U S A (2004) 17.86
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Mapping cortical change across the human life span. Nat Neurosci (2003) 8.98
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Longitudinal mapping of cortical thickness and brain growth in normal children. J Neurosci (2004) 7.30
The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol (2004) 7.07
Construction of a 3D probabilistic atlas of human cortical structures. Neuroimage (2007) 7.04
Dynamics of gray matter loss in Alzheimer's disease. J Neurosci (2003) 7.03
Automatic classification of MR scans in Alzheimer's disease. Brain (2008) 6.71
Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage (2008) 6.58
A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement (2008) 6.39
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med (2006) 6.02
Sexual dimorphism of brain developmental trajectories during childhood and adolescence. Neuroimage (2007) 5.86
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
The LONI Pipeline Processing Environment. Neuroimage (2003) 5.47
Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage (2011) 5.24
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage (2004) 5.07
Mild cognitive impairment: ten years later. Arch Neurol (2009) 5.02
Mapping brain asymmetry. Nat Rev Neurosci (2003) 4.99
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol (2004) 4.66
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage (2007) 4.41
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database. Neuroimage (2010) 4.28
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci (2004) 4.14
Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia. Neuroimage (2004) 4.13
Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage (2007) 4.07
Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain (2006) 4.07
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage (2006) 3.85
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Atlas-based whole brain white matter analysis using large deformation diffeomorphic metric mapping: application to normal elderly and Alzheimer's disease participants. Neuroimage (2009) 3.74
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Dynamics of the hippocampus during encoding and retrieval of face-name pairs. Science (2003) 3.67
Mapping brain maturation. Trends Neurosci (2006) 3.60
Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA (2010) 3.58
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Testing the right target and right drug at the right stage. Sci Transl Med (2011) 3.55
3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain (2007) 3.53
Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease. Neuroimage (2011) 3.47
Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage (2008) 3.40
Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia. J Magn Reson Imaging (2002) 3.34
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
A multimodal, multidimensional atlas of the C57BL/6J mouse brain. J Anat (2004) 3.28
Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage (2010) 3.27
Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol (2003) 3.26
Sex differences in cortical thickness mapped in 176 healthy individuals between 7 and 87 years of age. Cereb Cortex (2006) 3.23
Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology (2005) 3.14
Fast and robust multi-atlas segmentation of brain magnetic resonance images. Neuroimage (2009) 3.13
Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol (2006) 3.11
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11